Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy. Till, J. E., Abdalla, A., Bhagwat, N., Black, T. A., Wang, Z., Yee, S. S., Gherardini, P., Kitch, L. J., Selinsky, C., Lyman, J., LaVallee, T., Fisher, G. A., Rahma, O. E., Ko, A. H., Wainberg, Z. A., Wolff, R. A., O'Reilly, E., Vonderheide, R. H., O'Hara, M. H., Carpenter, E. L. LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.4122
View details for Web of Science ID 000708120602222